Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
| ▸ | ACR | P10323 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624875 | 0.98 | PRSS1 (0.49) | PRSS1ACRCA1CA2TDP1 | |
| SCHEMBL3624877 | 0.98 | PRSS1 (0.49) | PRSS1ACRCA1CA2TDP1 | |
| SCHEMBL12306095 | 0.90 | NPC1 (0.53) | PRSS1ACRCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL12416648 | 0.90 | NPC1 (0.53) | PRSS1ACRCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL10613386 | 0.86 | MAPT (0.50) | PRSS1ACRCA1CA2CYP1A2 | |
| SCHEMBL12417145 | 0.86 | TP53 (0.62) | CA1CA2CYP1A2CYP2C19CYP19A1 | |
| SCHEMBL12417148 | 0.86 | TP53 (0.62) | CA1CA2CYP1A2CYP2C19CYP19A1 | |
| SCHEMBL3795096 | 0.86 | L3MBTL1 (0.58) | PRSS1ACRCA1CA2L3MBTL1 | |
| SCHEMBL12416684 | 0.86 | L3MBTL1 (0.58) | PRSS1ACRCA1CA2L3MBTL1 | |
| SCHEMBL12416800 | 0.86 | S100B (0.58) | PRSS1ACRCA1CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | PRSS1 1535/4885ACR 1111/4885CA1 1082/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | PRSS1 1535/4885ACR 1111/4885CA1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.